Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Evaluation of <i>in vitro</i> activity of LNP-siRNA on LX-2 cells stimulated by 2 ng/mL of TGF-β. by Ying-Chou Chen (263436)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Accumulated immature APP in response to IDN5706 is degraded by Atg5-dependent autophagy. by Viviana A. Cavieres (500139)

Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G. by Régis Cohen (11419436)

Subjects:

Three Ca_V3.3 variants left-shift the window current, while the A398V completely abolishes the window current. by Yousra El Ghaleb (22075892)

Subjects:

Fig 5 - by Fatemeh Mohammadkhani (15927311)

Time-adjusted survival curve for IL-6 and renalase among patients with COVID-19 disease (A) For composite outcome^a: High renalase + High IL-6; High renalase + Low IL-6;... by Basmah Safdar (12213257)

Mean and standard deviation values of <i>p</i> and <i>q</i> distributions shown in Fig 5, and generated with a rolling, overlapping time window of 252 days. by Héctor Raúl Olivares-Sánchez (13014866)

Immunohistochemical staining and analysis of NF-κB activation in cytokine- and α-MSH-treated Caco-2 cells. by Judit Váradi (507449)